Hepatology (Liver, Pancreatic, Gall Bladder) | New Developments

Ascletis Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Galmed and Ascletis Subsidiary Gannex Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41

Lead Product(s): ASC41,Aramchol

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ASC41

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Galmed Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration September 10, 2020

Details:

ASC41 is an oral thyroid hormone receptor beta agonist and Aramchol is a novel synthetic small molecule, a conjugate of cholic acid and arachidic acid, linked by a stable amide group. The team will work together combining both the therapies for the treatment of NASH.

Kaleido Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Kaleido Biosciences Announces Presentation of Data for Microbiome Metabolic Therapy KB174 for Hepatic Encephalopathy

Lead Product(s): KB174

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: KB174

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 27, 2020

Details:

The results include details on the effects of KB174 on microbiome nitrogen metabolism in a clinical study in patients with cirrhosis, improved tolerability for KB174 relative to lactulose, as well as effects of MMTs on bacterial composition in patient samples ex vivo.

Axcella Health

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Results of Axcella’s AXA1665-001 Clinical Study Published in Clinical and Translational Gastroenterology

Lead Product(s): AXA1665

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1665

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 17, 2020

Details:

Data support AXA1665’s potential to address hyperammonemia, amino acid dysregulation and physical dysfunction in subjects with cirrhosis.

Axcella Health

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Axcella Reports Positive Top-Line Data from AXA1665-002 and Second Quarter Financial Results

Lead Product(s): AXA1665

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1665

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 05, 2020

Details:

Top-line data from AXA1665-002 show dose dependent improvements in markers of cognitive function and amino acid metabolism; both AXA1665 doses safe and well tolerated for 12 Weeks.

Poseida Therapeutics, Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Malin-backed Poseida Therapeutics files for IPO on Nasdaq exchange

Lead Product(s): Gene Therapies

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $110.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering June 25, 2020

Details:

The expected IPO cash and its series D is earmarked for Poseida's leading candidate P-BCMA-101, an autologous CAR-T currently in a potentially registrational phase 2 trial for multiple myeloma.

Axcella Health

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Axcella Announces Patent Issuances Covering AXA1665

Lead Product(s): AXA1665

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1665

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 17, 2020

Details:

U.S. Patent 10,682,325 covers the composition of AXA1665 as well as other related EMM compositions. U.S. Patent 10,660,870 focuses on methods of use for these EMM compositions in treating a liver disease or disorder involving hyperammonemia and/or muscle wasting.

CN Bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

CN Bio and Cambridge University Identify Novel Regulatory Pathway Driving NASH

Lead Product(s): Undisclosed

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Cambridge University

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 09, 2020

Details:

The collaborative work uses CN Bio’s NASH model to help elucidate the complex cellular mechanisms that cause liver fibrosis.

Axcella Health

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Axcella to Report Top-Line Data from AXA1125-003 in Adult Subjects with NAFLD

Lead Product(s): AXA1125,AXA1957

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2020

Details:

AXA1125-003 is a clinical study assessing the impact of AXA1125 and AXA1957 on safety, tolerability and effects on structures and functions of the liver in adult with nonalcoholic fatty liver disease.